Locke Lord advised Imugene Ltd. on the transaction. Precision BioSciences, Inc. (Nasdaq: DTIL) announced it has completed a transaction with Imugene Limited (ASX: IMU) for global rights...
You must be a Standard 1 Year member to access this content.
Locke Lord advised MindImmune Therapeutics, Inc. on the deal. MindImmune Therapeutics Inc., a drug discovery company pioneering a new approach to treat Alzheimer’s disease and other...
You must be a Standard 1 Year member to access this content.
Locke Lord advised Nabsys on the deal. Nabsys announced an investment of $25 million by Hitachi High-Tech Corporation through the issuance and sale of the client’s Series...
You must be a Standard 1 Year member to access this content.
Locke Lord LLP advised Shanghai Haohai Biological Technology Co. on the deal. Shanghai Haohai Biological Technology Co., Ltd., a public company traded on the Hong Kong...
You must be a Standard 1 Year member to access this content.
